This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Doximity (DOCS) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Doximity (DOCS) reachead $40.88 at the closing of the latest trading day, reflecting a +0.62% change compared to its last close.
SOLV vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
SOLV vs. DOCS: Which Stock Is the Better Value Option?
LTH vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
LTH vs. DOCS: Which Stock Is the Better Value Option?
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
LTH vs. DOCS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LTH vs. DOCS: Which Stock Is the Better Value Option?
Doximity (DOCS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 27.27% and 5.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Doximity (DOCS) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Doximity (DOCS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 292.31% and 37.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why the Market Dipped But Doximity (DOCS) Gained Today
by Zacks Equity Research
Doximity (DOCS) closed the most recent trading day at $28.66, moving +1.49% from the previous trading session.
3 Medical Services Industry Stocks to Buy as Healthcare Wage Increases
by Urmimala Biswas
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ICLR, OGN and DOCS are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.
Doximity (DOCS) Stock Moves -1.24%: What You Should Know
by Zacks Equity Research
In the latest trading session, Doximity (DOCS) closed at $27.88, marking a -1.24% move from the previous day.
Doximity (DOCS) Stock Moves -1.23%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Doximity (DOCS) stood at $28.99, denoting a -1.23% change from the preceding trading day.
Doximity (DOCS) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Doximity (DOCS) closed the most recent trading day at $27.97, moving +0.5% from the previous trading session.
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
Doximity (DOCS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Company News for May 20, 2024
by Zacks Equity Research
Companies in The News Are: RBC,FLO,DOCS,GME
Doximity (DOCS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 25% and 1.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Ahead of Doximity (DOCS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Doximity (DOCS) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Organon (OGN) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 25.77% and 3.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Elevance Health Medpace and Doximity
by Zacks Equity Research
Elevance Health, Medpace and Doximity are part of the Zacks Industry Outlook article.
3 Medical Services Industry Stocks to Buy as Nursing Market Booms
by Urmimala Biswas
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, MEDP and DOCS are set to gain the most. However, staffing shortages continue to put brakes on growth.
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML